HC Wainwright restated their buy rating on shares of Ocugen (NASDAQ:OCGN - Free Report) in a research report released on Monday,Benzinga reports. They currently have a $7.00 price target on the stock.
Other analysts have also recently issued research reports about the stock. Maxim Group started coverage on shares of Ocugen in a research report on Tuesday, October 15th. They set a "buy" rating and a $4.00 price target on the stock. Chardan Capital reaffirmed a "buy" rating and set a $6.00 price target on shares of Ocugen in a research report on Friday.
Check Out Our Latest Stock Report on OCGN
Ocugen Trading Up 8.5 %
Shares of Ocugen stock traded up $0.08 during trading on Monday, hitting $1.07. The company's stock had a trading volume of 4,720,571 shares, compared to its average volume of 6,150,678. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.04 and a quick ratio of 1.04. Ocugen has a 52 week low of $0.35 and a 52 week high of $2.11. The stock has a market cap of $308.01 million, a price-to-earnings ratio of -5.63 and a beta of 3.75. The stock has a 50-day moving average price of $1.03 and a two-hundred day moving average price of $1.35.
Ocugen (NASDAQ:OCGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $1.14 million for the quarter. During the same quarter in the prior year, the business earned ($0.10) earnings per share. Equities research analysts anticipate that Ocugen will post -0.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Ocugen
Several institutional investors have recently made changes to their positions in the stock. Xponance Inc. acquired a new stake in shares of Ocugen in the 2nd quarter worth about $25,000. Baader Bank Aktiengesellschaft acquired a new stake in shares of Ocugen in the 2nd quarter worth about $35,000. Victory Capital Management Inc. acquired a new stake in shares of Ocugen in the 2nd quarter worth about $51,000. Headlands Technologies LLC acquired a new stake in shares of Ocugen in the 1st quarter worth about $66,000. Finally, Daiwa Securities Group Inc. acquired a new stake in shares of Ocugen in the 2nd quarter worth about $67,000. Institutional investors and hedge funds own 10.27% of the company's stock.
About Ocugen
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Further Reading
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
